MORF News and Press, Morphic Holding Inc. From 09/21/20

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Nex...

WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences: P...

Morphic Therapeutic (NASDAQ: MORF ) announces that collaboration partner and licensee AbbVie (NYSE: ABBV ) has exercised its option to develop its α v β 6  integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and ad...

AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a n...

Morphic (NASDAQ: MORF ) : Q2 GAAP EPS of -$0.52 beats by $0.04 . More news on: Morphic Holding, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Company’s first IND accepted by FDA for MORF-057 in IBD Phase 1 study expected to begin in third-quarter 2020 Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: M...

Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD IND filing on track for mid-year and phase 1 clinical trial expected third-quarter 2020 WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) -...

The following slide deck was published by Morphic Holding, Inc. in conjunction with this Read more ...

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president...

WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is sched...